TAM
NTLA icon

Tocqueville Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Tocqueville Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-15,450
Closed -$211K – 792
2018
Q4 		$211K Sell
15,450
-4,000
-21% -$74.3K ﹤0.01% 693
2018
Q3 		$557K Buy
19,450
+400
+2% +$11.6K 0.01% 600
2018
Q2 		$521K Buy
+19,050
New +$462K 0.01% 597

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Tocqueville Asset Management's NTLA Position: Q1 2019 in Review

Tocqueville Asset Management sold out of Intellia Therapeutics (NTLA) in Q1 2019, closing a stake of 15,450 shares — an estimated $211K sold.

Tocqueville Asset Management first reported a position in NTLA in Q2 2018 and held it in 3 quarters. The position peaked at $557K in Q3 2018. 148 funds tracked by Wall St. Rank hold NTLA as of Q1 2019.

  • Tocqueville Asset Management reported no remaining Intellia Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Tocqueville Asset Management sold 15,450 Intellia Therapeutics shares in Q1 2019, an estimated $211K.
  • Tocqueville Asset Management first reported a position in Intellia Therapeutics in Q2 2018 and held it in 3 quarters.
  • Tocqueville Asset Management's Intellia Therapeutics position peaked at $557K in Q3 2018.
  • 148 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2019.

Based on Tocqueville Asset Management's 13F filing for Q1 2019, filed 30 Apr 2019.